Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
ButylphthalideCardiac ArrestNeuroprotective Drugs
Interventions
DRUG

Butylphthalide and Sodium Chloride Injection

All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.

DRUG

Saline Solution

All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.

Trial Locations (1)

100020

RECRUITING

Beijing Chao-Yang Hospital, Beijing

All Listed Sponsors
lead

Tang Ziren

OTHER

NCT06572085 - Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients | Biotech Hunter | Biotech Hunter